BioSpecifics Technologies Corp (NASDAQ: BSTC), a biopharmaceutical company, announced yesterday that it has named life sciences industry veteran Kevin Buchi as chief executive officer of BioSpecifics.

Buchi will also serve on the firm's board of directors.

Presently, Buchi is the chairman of the board of directors at Dicerna Pharmaceuticals and a director of Amneal Pharmaceuticals and Benitec Biopharma Ltd. He was most recently president and chief executive officer at TetraLogic Pharmaceuticals from 2012 to 2016. Earlier, he served as Impax Laboratories' interim president and chief executive officer from December 2016 to March 2017. He also served as corporate vice president of Global Branded Products at Teva Pharmaceutical from 2011 to May 2012 and as chief executive officer of Cephalon, which was acquired by Teva in October 2011. He had been at the company since 1991.